FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023685327> ?p ?o ?g. }

• W2023685327 endingPage "92" @default.
• W2023685327 startingPage "85" @default.
• W2023685327 abstract "Multiple sclerosis (MS) is a chronic immune-mediated inflammatory demyelinating disease of the central nervous system. Interferon-β (IFN-β) has been used as the first line therapy for MS treatment in Japan, but patients treated with IFN-β may develop antibodies, known as neutralizing antibodies (NAbs), which abrogate its therapeutic effects. Intramuscular IFN-β 1a and subcutaneous IFN-β 1b are currently available in Japan, but large-scale studies evaluating the prevalence and clinical implications of NAbs against these IFN-β preparations in MS patients have only been performed in Caucasian populations. NAbs positivity has been reported to be associated with HLA-DRB1 alleles, suggesting that the positivity might differ among populations with distinct genetic backgrounds. Clinical information and sera were collected from 229 consecutive MS patients treated with IFN-β in 4 centers in Japan. Sera were tested for NAbs using a luciferase reporter gene assay. In total, 5.2% of IFN-β-1a-treated patients (4/77) and 30.3% of IFN-β-1b-treated patients (46/152) were positive for Nabs. The frequency of NAbs was highest in patients treated for 13 to 24 months. Clinical relapse and contrast-enhancing lesions in the magnetic resonance imaging increased together with NAbs titers in this group. In conclusion, the prevalence of NAbs in Japanese MS patients is similar to that in Caucasian populations and is associated with an increase in disease activity. Therefore, routine NAbs testing is recommended also in Asian populations to ensure the early identification of patients who would benefit from a change in therapy." @default.
• W2023685327 created "2016-06-24" @default.
• W2023685327 creator A5003748942 @default.
• W2023685327 creator A5004404671 @default.
• W2023685327 creator A5015754502 @default.
• W2023685327 creator A5022594173 @default.
• W2023685327 creator A5022725758 @default.
• W2023685327 creator A5049801477 @default.
• W2023685327 creator A5050470835 @default.
• W2023685327 creator A5051512652 @default.
• W2023685327 creator A5061519516 @default.
• W2023685327 creator A5068037677 @default.
• W2023685327 creator A5073117349 @default.
• W2023685327 creator A5077929630 @default.
• W2023685327 creator A5089996126 @default.
• W2023685327 date "2012-01-01" @default.
• W2023685327 modified "2023-09-25" @default.
• W2023685327 title "Neutralizing Antibodies Are Associated with a Reduction of Interferon-β Efficacy during the Treatment of Japanese Multiple Sclerosis Patients" @default.
• W2023685327 cites W1996963540 @default.
• W2023685327 cites W2029745420 @default.
• W2023685327 cites W2050758839 @default.
• W2023685327 cites W2054776967 @default.
• W2023685327 cites W2073202918 @default.
• W2023685327 cites W2075126054 @default.
• W2023685327 cites W2086332151 @default.
• W2023685327 cites W2105490558 @default.
• W2023685327 cites W2106710384 @default.
• W2023685327 cites W2126400932 @default.
• W2023685327 cites W2132661548 @default.
• W2023685327 cites W2134031733 @default.
• W2023685327 cites W2151491950 @default.
• W2023685327 cites W2153053990 @default.
• W2023685327 cites W2157690102 @default.
• W2023685327 cites W2161552221 @default.
• W2023685327 cites W2164490190 @default.
• W2023685327 cites W2174908949 @default.
• W2023685327 cites W2175739361 @default.
• W2023685327 cites W2313649737 @default.
• W2023685327 doi "https://doi.org/10.1620/tjem.228.85" @default.
• W2023685327 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22976494" @default.
• W2023685327 hasPublicationYear "2012" @default.
• W2023685327 type Work @default.
• W2023685327 sameAs 2023685327 @default.
• W2023685327 citedByCount "14" @default.
• W2023685327 countsByYear W20236853272013 @default.
• W2023685327 countsByYear W20236853272014 @default.
• W2023685327 countsByYear W20236853272015 @default.
• W2023685327 countsByYear W20236853272016 @default.
• W2023685327 crossrefType "journal-article" @default.
• W2023685327 hasAuthorship W2023685327A5003748942 @default.
• W2023685327 hasAuthorship W2023685327A5004404671 @default.
• W2023685327 hasAuthorship W2023685327A5015754502 @default.
• W2023685327 hasAuthorship W2023685327A5022594173 @default.
• W2023685327 hasAuthorship W2023685327A5022725758 @default.
• W2023685327 hasAuthorship W2023685327A5049801477 @default.
• W2023685327 hasAuthorship W2023685327A5050470835 @default.
• W2023685327 hasAuthorship W2023685327A5051512652 @default.
• W2023685327 hasAuthorship W2023685327A5061519516 @default.
• W2023685327 hasAuthorship W2023685327A5068037677 @default.
• W2023685327 hasAuthorship W2023685327A5073117349 @default.
• W2023685327 hasAuthorship W2023685327A5077929630 @default.
• W2023685327 hasAuthorship W2023685327A5089996126 @default.
• W2023685327 hasBestOaLocation W20236853271 @default.
• W2023685327 hasConcept C126322002 @default.
• W2023685327 hasConcept C159654299 @default.
• W2023685327 hasConcept C203014093 @default.
• W2023685327 hasConcept C2776178377 @default.
• W2023685327 hasConcept C2779134260 @default.
• W2023685327 hasConcept C2780640218 @default.
• W2023685327 hasConcept C2780892749 @default.
• W2023685327 hasConcept C32611913 @default.
• W2023685327 hasConcept C71924100 @default.
• W2023685327 hasConcept C8891405 @default.
• W2023685327 hasConceptScore W2023685327C126322002 @default.
• W2023685327 hasConceptScore W2023685327C159654299 @default.
• W2023685327 hasConceptScore W2023685327C203014093 @default.
• W2023685327 hasConceptScore W2023685327C2776178377 @default.
• W2023685327 hasConceptScore W2023685327C2779134260 @default.
• W2023685327 hasConceptScore W2023685327C2780640218 @default.
• W2023685327 hasConceptScore W2023685327C2780892749 @default.
• W2023685327 hasConceptScore W2023685327C32611913 @default.
• W2023685327 hasConceptScore W2023685327C71924100 @default.
• W2023685327 hasConceptScore W2023685327C8891405 @default.
• W2023685327 hasIssue "2" @default.
• W2023685327 hasLocation W20236853271 @default.
• W2023685327 hasLocation W20236853272 @default.
• W2023685327 hasOpenAccess W2023685327 @default.
• W2023685327 hasPrimaryLocation W20236853271 @default.
• W2023685327 hasRelatedWork W1585886116 @default.
• W2023685327 hasRelatedWork W162776443 @default.
• W2023685327 hasRelatedWork W2025909013 @default.
• W2023685327 hasRelatedWork W2058632873 @default.
• W2023685327 hasRelatedWork W2089887933 @default.
• W2023685327 hasRelatedWork W2461201667 @default.
• W2023685327 hasRelatedWork W2617222556 @default.
• W2023685327 hasRelatedWork W2940753023 @default.
• W2023685327 hasRelatedWork W4238477398 @default.
• W2023685327 hasRelatedWork W4290988590 @default.

• next